Ciluprevir
Alternative Names: BILN 2061 ZW; BILN-2061Latest Information Update: 02 Oct 2021
At a glance
- Originator Boehringer Ingelheim (Canada); Boehringer Ingelheim Pharma KG
- Developer Boehringer Ingelheim Pharma KG
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 11 Dec 2008 Discontinued - Phase-II for Hepatitis C in Canada (PO)
- 11 Dec 2008 Discontinued - Phase-II for Hepatitis C in Germany (PO)
- 01 Jun 2004 Suspended - Phase-II for Hepatitis C in Canada (PO)